Cargando…
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638078/ https://www.ncbi.nlm.nih.gov/pubmed/37253975 http://dx.doi.org/10.1038/s41391-023-00682-2 |
| _version_ | 1785146550644637696 |
|---|---|
| author | Ohlmann, Carsten-Henning Jäschke, Michelle Jaehnig, Peter Krege, Susanne Gschwend, Jürgen Rexer, Heidrun Junker, Kerstin Zillmann, Roger Rüssel, Christoph Hellmis, Eva Suttmann, Henrik Janssen, Martin Marin, Jan Hübner, Andreas Mathers, Michael Gleißner, Jochen Scheffler, Michael Feyerabend, Susan Telle, Jens Klier, Jörg Stöckle, Michael |
| author_facet | Ohlmann, Carsten-Henning Jäschke, Michelle Jaehnig, Peter Krege, Susanne Gschwend, Jürgen Rexer, Heidrun Junker, Kerstin Zillmann, Roger Rüssel, Christoph Hellmis, Eva Suttmann, Henrik Janssen, Martin Marin, Jan Hübner, Andreas Mathers, Michael Gleißner, Jochen Scheffler, Michael Feyerabend, Susan Telle, Jens Klier, Jörg Stöckle, Michael |
| author_sort | Ohlmann, Carsten-Henning |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10638078 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106380782023-11-15 Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial Ohlmann, Carsten-Henning Jäschke, Michelle Jaehnig, Peter Krege, Susanne Gschwend, Jürgen Rexer, Heidrun Junker, Kerstin Zillmann, Roger Rüssel, Christoph Hellmis, Eva Suttmann, Henrik Janssen, Martin Marin, Jan Hübner, Andreas Mathers, Michael Gleißner, Jochen Scheffler, Michael Feyerabend, Susan Telle, Jens Klier, Jörg Stöckle, Michael Prostate Cancer Prostatic Dis Correction Nature Publishing Group UK 2023-05-30 2023 /pmc/articles/PMC10638078/ /pubmed/37253975 http://dx.doi.org/10.1038/s41391-023-00682-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Ohlmann, Carsten-Henning Jäschke, Michelle Jaehnig, Peter Krege, Susanne Gschwend, Jürgen Rexer, Heidrun Junker, Kerstin Zillmann, Roger Rüssel, Christoph Hellmis, Eva Suttmann, Henrik Janssen, Martin Marin, Jan Hübner, Andreas Mathers, Michael Gleißner, Jochen Scheffler, Michael Feyerabend, Susan Telle, Jens Klier, Jörg Stöckle, Michael Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title | Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title_full | Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title_fullStr | Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title_full_unstemmed | Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title_short | Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
| title_sort | correction to: lhrh sparing therapy in patients with chemotherapy-naïve, mcrpc treated with abiraterone acetate plus prednisone: results of the randomized phase ii spare trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638078/ https://www.ncbi.nlm.nih.gov/pubmed/37253975 http://dx.doi.org/10.1038/s41391-023-00682-2 |
| work_keys_str_mv | AT ohlmanncarstenhenning correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT jaschkemichelle correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT jaehnigpeter correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT kregesusanne correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT gschwendjurgen correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT rexerheidrun correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT junkerkerstin correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT zillmannroger correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT russelchristoph correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT hellmiseva correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT suttmannhenrik correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT janssenmartin correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT marinjan correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT hubnerandreas correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT mathersmichael correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT gleißnerjochen correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT schefflermichael correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT feyerabendsusan correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT tellejens correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT klierjorg correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial AT stocklemichael correctiontolhrhsparingtherapyinpatientswithchemotherapynaivemcrpctreatedwithabirateroneacetateplusprednisoneresultsoftherandomizedphaseiisparetrial |